Clear Scientific News

Cambridge MA | Sept 2024 CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Clear Scientific, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for conditions and diseases caused by an excess of harmful substances in the body, today announced positive topline data from the First-in-Human Phase 1 clinical trial of its therapeutic CS-1103 that demonstrate a favorable safety and tolerability profile. All thirty-two healthy participants recruited, d

Cambridge MA | June 2024 Clear Scientific is featured in the June 24, 2024 issue of Eureka: A Dose of Science, a multimedia platform that continually searches for creative ways to talk about science, including breaking news science and the people behind it. The article, titled “A Novel Therapeutic Takes Aim at the Fentanyl and Meth Crisis,” [A Novel Therapeutic Takes Aim at the Fentanyl and Meth Crisis | Eureka blog (criver.com)] describes Clear's efforts to develop an effec

Montreal, Canada | June, 2024 Dr. Xinhua Li, Executive Vice President of Drug Development at Clear Scientific Inc, a Cambridge, MA biotech, presented a talk titled: A Novel Approach to Treat Xylazine and Opioid Intoxication at the 86th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD). The presentation outlined Clear Scientific’s approach using a novel sequestrant CS-1103 to treat intoxication from combinations of fentanyl and xylazine. The immed

Cambridge, MA | May 22, 2024 Clear Scientific is featured in the latest episode of Vital Science, a podcast unveiling the compelling stories behind bold science told through the perspectives of those discovering, developing, and receiving life-changing therapies, sponsored by Charles River Laboratories (Vital Science Podcast | Charles River (criver.com), Season 5 Episode 8). The podcast, entitled Combatting Drug Overdose from Methamphetamine, Fentanyl, and Polydrug, describe

Atlanta, GA | April 1, 2024 Clear Scientific presented a poster titled: Hope in Methamphetamine Addiction and Overdose, Authors: P. Oliver, C. Leggett, M. Vara, A. Mager, X. Li, M. Zakin, S. Shetty, at the 2024 Rx and Illicit Drug Summit (https://www.hmpglobalevents.com/rx-summit). The poster outlined CS Inc.’s approach using a novel sequestrant CS-1103 to treat methamphetamine use disorder, particularly overdose. The immediate sequestration of methamphetamine leads to rapid

Cambridge, MA | Nov 2023 Clear Scientific, a clinical-stage biopharmaceutical company, today announced an award from the National Institute on Drug Abuse (NIDA) of the NIH, with a total potential value of $15M, to support development of CS-1103, the first therapeutic that both rapidly deactivates and removes fentanyl from the body. Fentanyl misuse is a nationwide crisis, with over 1M emergency department visits and 73,000 overdose deaths annually. There are substantial defic

Cambridge, MA | Nov 2023 Clear Scientific, a clinical-stage biopharmaceutical company, today announced a $12M award from the National Institute on Drug Abuse of the NIH to support development of CS-1103, an antidote for methamphetamine overdose, through Phase 2 clinical trials. This is the first step in our development of a broad-spectrum antidote for illicit and prescription stimulants. Stimulant misuse is a major worldwide public health crisis for which there are no FDA-ap

Cambridge, MA | Oct 2023 Clear Scientific Inc., a Cambridge MA based biopharmaceutical company, announced that the FDA has approved its Investigational New Drug (IND) application for CS-1103, the first antidote for stimulant overdose, granting the company permission to initiate its Phase 1 First-in-Human clinical trial. Overdose from the stimulants methamphetamine and cocaine alone result in over 1,000,000 emergency department visits per year, with over 60,000 deaths, costin

Boston, MA | August 2023 On August 17th 2023 Winston Henderson, General Counsel of Clear Scientific Inc., participated as a panelist in L-SPRINT, a program sponsored by the National Institute on Drug Abuse (NIDA) and Babson College in Boston, MA. L-SPRINT’s purpose is to provide early-stage substance use disorder (SUD) researchers with the skills and knowledge they need to launch and run successful biotech and pharmaceutical companies. The program aims to promote entrepreneu

Denver, CO | June 2023 Clear Scientific presented a poster titled: A Novel Approach to Treat Fentanyl Intoxication, Authors: X. Li, P. Oliver, M. Vara, C. Leggett, S. Shetty, M. Zakin, at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD). The poster outlined CS Inc.’s approach using a novel sequestrant CS-1103 to treat fentanyl intoxication. The immediate sequestration of fentanyl leads to rapid draining of fentanyl from the brain resto

Cambridge, MA | May 2023 Clear Scientific's CS 1103 antidote was featured in Charles River Laboratories Eureka Blog : Drug Modality Game Changers. Currently in development are both an injectable drug and an oral drug. The injectable functions as a sequestrant, cleaning the bloodstream of certain narcotics (namely fentanyl, methamphetamine and cocaine) and helping the body to rapidly clear it in urine in a matter of minutes. The oral medication reduces the absorption of the

Cambridge, MA | May 2023 Shekar Shetty, CEO and Dr. Piercen Oliver, VP R&D of Clear Scientific presented at the Charles River Sixth Annual World Congress, a global event. The conference is an ongoing effort to progress and raise awareness to how advanced modalities are disrupting drug development. This event showcased how advanced modalities are shaping drug development through presentations from biopharmaceutical companies, academia, panel discussions, investors, and patie

Boston, MA | Sept 2022 There is an urgent need for a safe rapidly acting antidote for methamphetamine. Meth is the fastest growing drug of abuse in the U.S., representing over 798,000 annual emergency department visits, with deaths increasing 14-fold since 2015 (32,856 deaths in 2021 alone), yet no current therapeutics are available to treat meth intoxication. A therapeutic that reverses meth intoxication would save lives. Dr. Roneet Lev is an emergency and addiction doctor w